MHRA
- Local brand name: Herceptin
- Status: approved
🇬🇧 Herceptin in United Kingdom
NICE has issued 15 UK HTA decisions
Marketing authorisation
Health technology assessment
15 decisions from NICE for Herceptin in United Kingdom.
NICE TA1112 — — Appraisal terminated
- Indication assessed: treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)
NICE made a decision to terminate the appraisal of Herceptin for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments. This decision means that NICE will not make a recommendation on the use of Herceptin for this specific indication. The cost-effectiveness of Herceptin was not reported as part of this decision.
NICE TA992 — ✗ Not recommended
- Indication assessed: treating HER2-low metastatic or unresectable breast cancer after chemotherapy
NICE made a decision not to recommend Herceptin for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. This decision was made without a reported cost-effectiveness analysis or a patient access scheme. No commercial arrangement was considered.
NICE TA983 — ✗ Not recommended
- Indication assessed: untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma
NICE made a decision not to recommend Herceptin for the treatment of untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. This decision was made without a reported cost-effectiveness analysis, as the ICER was not provided. There were no restrictions or conditions placed on the use of Herceptin for this indication.
NICE TA976 — — Appraisal terminated
- Indication assessed: treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
NICE made a decision to terminate the appraisal of Herceptin for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy. This decision means that NICE will not make a recommendation on the use of Herceptin for this specific indication. The decision to terminate the appraisal was made without a recommendation on the cost-effectiveness of Herceptin, as the cost basis is not reported.
NICE TA879 — — Appraisal terminated
- Indication assessed: treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)
NICE made a decision to terminate the appraisal of Herceptin for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer. This decision was made without a recommendation on the cost-effectiveness of the treatment. The appraisal was terminated, which means that NICE did not make a final decision on the use of Herceptin for this indication.
NICE TA862 — ✓ Recommended
- Indication assessed: treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
NICE recommended Herceptin for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Herceptin.
NICE TA786 — ✓ Recommended
- Indication assessed: treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
NICE recommended Herceptin for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. This decision was made based on a commercial arrangement and a patient access scheme. No restrictions were placed on the use of Herceptin.
NICE TA704 — ◐ Recommended with restrictions
- Indication assessed: treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
- Restriction: It is recommended only if the conditions in the managed access agreement are followed.
NICE recommended Herceptin for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies, but with restrictions. This decision was made with the conditions of a managed access agreement in place. The use of Herceptin is only recommended if these conditions are followed.
NICE TA632 — ✓ Recommended
- Indication assessed: adjuvant treatment of HER2-positive early breast cancer
NICE recommended Herceptin for the adjuvant treatment of HER2-positive early breast cancer. This decision was made based on a commercial arrangement, indicating that the manufacturer agreed to a specific price or reimbursement terms. There were no restrictions or conditions placed on the use of Herceptin for this indication.
NICE TA612 — ✓ Recommended
- Indication assessed: extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
NICE recommended Herceptin for the extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. This decision was made based on a commercial arrangement, indicating that the manufacturer agreed to a specific price or reimbursement terms. There were no restrictions or conditions placed on the use of Herceptin for this indication.
NICE TA509 — ✓ Recommended
- Indication assessed: treating HER2-positive breast cancer
NICE recommended Herceptin for treating HER2-positive breast cancer. This decision was made without a reported cost-effectiveness analysis. There were no restrictions or conditions placed on the use of Herceptin.
NICE TA458 — ✓ Recommended
- Indication assessed: treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE recommended Herceptin for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Herceptin.
NICE TA257 — ✗ Not recommended
- Indication assessed: the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2
NICE did not recommend Herceptin for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2. This decision was made without a reported cost-effectiveness analysis or consideration of a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Herceptin for this indication.
NICE TA208 — ✓ Recommended
- Indication assessed: the treatment of HER2-positive metastatic gastric cancer
NICE recommended Herceptin for the treatment of HER2-positive metastatic gastric cancer. This decision was made without a specific cost basis being reported. There were no restrictions or conditions placed on the use of Herceptin for this indication.
NICE TA34 — ✓ Recommended
- Indication assessed: the treatment of advanced breast cancer
NICE recommended Herceptin for the treatment of advanced breast cancer. This decision was made without a reported cost-effectiveness analysis or a patient access scheme. No commercial arrangement or restriction was applied to the recommendation.
Herceptin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Herceptin approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Herceptin in United Kingdom?
Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Herceptin been assessed by UK health technology agencies?
Yes — 15 UK HTA decisions on record from NICE.